COVID vaccine makers pivot to new products and regional drug sovereignty

According to policy analyst Belén Tarrafeta, the COVID-19 crisis redefined drugs as strategic goods linked to sovereignty, reshaping global pharma geopolitics. Moderna, after pausing its African mRNA plant, announced promising phase-III results for a personalized melanoma vaccine, signaling a shift toward cancer immunotherapy. AstraZeneca, once criticized for its vaccine rollout, is now focusing on rare-cancer treatments and has secured new UK investment after negotiating higher drug-budget thresholds.

Pfizer, after facing scrutiny over vaccine contracts, is diversifying into anti-obesity treatments following a major acquisition. The experience also spurred African countries to pursue local vaccine production, emphasizing regulation, technology transfer and sustainable demand. These trends illustrate a broader move toward supply security and diversified revenue streams in the post-pandemic pharmaceutical sector.